1. TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model.
TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 (50 mg/kg intraperitoneally three times a week for 3 weeks) reduced the number of circulating AML cells and prolonged survival of NSG mice engrafted with primary AML cells compared with the vehicle-treated mice. A, survival curves (N = 8/group) of vehicle-treated (control) and TH-302–treated mice. Line indicates onset and duration of treatment. B, total numbers of mononuclear cells (MN) or total human AML cells were determined in blood by FACS analysis after staining for huCD45 (N = 2 and 3 for control and TH-302–treated mice, respectively). C, PIMO immunostaining of bone marrow (BM) sections from control or TH-302–treated mice euthanized at the end of the treatment; 20 × magnification. D, survival curves of secondary transplant mice (N = 5/group). NSG mice were transplanted with 0.01 or × 106 bone marrow cells isolated from primary recipients (A) treated with control or TH-302.
Juliana Benito et al. Clin Cancer Res 2016;22:
©2016 by American Association for Cancer Research